Peptide Genomics & Personalized Therapy

The future of peptide therapy: genetics-based protocol optimization

200+
Genes affecting peptide response
3x
Efficacy improvement with genetics

The One-Size-Fits-All Problem

Current peptide dosing is based on averages from clinical trials — typically 70kg male subjects. But your genetics determine how you actually metabolize, respond to, and benefit from peptides.

Same peptide, same dose, different results. Genetics explain why some people thrive on low doses while others need 3x the amount — and why side effects vary so dramatically.

What Science Already Knows

CYP Enzymes

CYP2D6, CYP3A4, and other cytochrome enzymes affect how quickly peptides are metabolized. Slow metabolizers need lower doses; fast metabolizers may need more.

APOE Gene

ApoE4 carriers have higher Alzheimer's risk and may respond differently to cognitive peptides. Affects BPC-157, Selank, and nootropic protocols.

GH/IGF-1 Genetics

Variations in the GHR gene affect how well GH secretagogues work. Some people are "non-responders" due to genetic variants.

GLP-1 Receptor

Variants in the GLP-1 receptor gene (GLP1R) affect how well GLP-1 agonists work for weight loss. Explains the 15-25% non-responder rate.

Genes That Matter for Peptide Therapy

Metabolism & Dosing

Response & Efficacy

Risk & Safety

How Genetic Testing Helps

1. Optimal Dosing

Know whether you're a slow, normal, or fast metabolizer. Adjust peptide doses accordingly from the start.

2. Predict Response

Know if you'll likely respond to a peptide before trying it. Avoid wasted time and money on unlikely responders.

3. Reduce Side Effects

Know your risk profile. Adjust protocol to minimize adverse effects based on your genetics.

4. Personalized Stacks

Build stacks based on your genetic profile rather than generic protocols.

The Future: Precision Peptide Therapy

Within the next 5-10 years, peptide protocols will be prescribed based on genetic profiles: